The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say.
Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively seeking out the lesser-known Novavax for their updated booster this fall.
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. Recently, Zacks.com users have been paying close ...